Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by duskwon Oct 05, 2012 3:53pm

379 Views

Post# 20454414

RE: RE: RE: RE: RE: RE: Impressive.

I disagree with this comment. They have sold nearly $90 million of precision Ag product in the past 18 months. That's nothing to scoff at. As I've said many times before - revenue isn't a huge problem - it's the fact the revenue is too low compared to expenses. There are several ways to remedy that including strategic initiatves (i.e. merger or acquision).

"There might be room for a low cost player somewheres in the US but I don't think its these guys. These guys don't seem to know what to market."

Bullboard Posts

Mid-year review: How has gold been performing?